Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A, Brahmbhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave ME, Collins CC, Wang Y.
Lin D, et al. Among authors: crea f.
Oncotarget. 2015 Jan 30;6(3):1806-20. doi: 10.18632/oncotarget.2809.
Oncotarget. 2015.
PMID: 25544761
Free PMC article.